S&P 500 falls on pressure from retail stocks, weak jobless claims
Wednesday
H.C. Wainwright analysts have maintained a Buy rating on Insmed (NASDAQ:INSM) shares, with a price target of $90.00. The firm’s analysts recently attended the 2025 Annual MDA Conference in Dallas, where they observed Insmed’s presentation of a novel gene therapy for Duchenne muscular dystrophy (DMD). The therapy utilizes an adeno-associated virus (AAV) based RNA end joining approach to produce a mid-length dystrophin protein, which is essential for muscle function. The company maintains a strong financial position with a current ratio of 5.45, indicating robust liquidity to support its research initiatives.
Insmed’s research, presented at the conference, involves splitting large genes into two components that are delivered into cells using two separate AAV vectors. Once inside the cell, the RNA segments are transcribed, and their dimerization domains mediate binding. This process recruits the spliceosome complex, which facilitates the joining of the RNAs to form a full-length mRNA. The resulting mid-length dystrophin protein includes domains critical for dystrophin function, which have been shown to be essential in recent research.
The gene therapy has been tested in mdx mice, a model for DMD, where it was administered systemically shortly after birth. The treated mice demonstrated significant improvement in muscle force when assessed at approximately four months of age. The positive results suggest that this approach could offer a new way to restore normal dystrophin function in DMD patients, provided it exhibits an acceptable safety profile in human trials.
The analysts at H.C. Wainwright highlight the potential of Insmed’s REJ technology to include additional domains in the dystrophin protein, which could be crucial for its normal function. The firm reiterates its Buy rating and $90 price target for Insmed stock, signaling confidence in the company’s innovative approach to tackling DMD. With revenue growth of 19.17% and an overall Financial Health score of FAIR according to InvestingPro, investors can access comprehensive analysis and additional insights through the platform’s detailed Pro Research Report, available along with 1,400+ other top stocks.
In other recent news, Insmed Incorporated has been the focus of several analyst updates and regulatory developments. RBC Capital Markets has reaffirmed an Outperform rating on Insmed, maintaining a price target of $100, citing confidence in the company’s TPIP treatment and its potential to significantly improve Pulmonary Vascular Resistance and the 6-Minute Walk Distance. Similarly, Truist Securities has maintained a Buy rating with a price target of $108, expressing optimism about upcoming TPIP data for pulmonary arterial hypertension, which could precede the commercial launch of brensocatib in 2025. UBS has also raised its price target for Insmed to $110, maintaining a Buy rating, as they anticipate positive outcomes from the Phase 2 trial of TPIP.
Moreover, the U.S. Food and Drug Administration has set a target action date of August 12, 2025, for Insmed’s drug brensocatib, intended for the treatment of non-cystic fibrosis bronchiectasis. The FDA’s decision not to hold an advisory committee meeting suggests a smooth review process, as the drug undergoes Priority Review. RBC Capital has highlighted the potential of brensocatib to be a successful launch, projecting peak sales of $8.2 billion in the bronchiectasis market. Insmed’s comprehensive pipeline, which includes Arikayce and TPIP, is anticipated to contribute significantly to the company’s valuation. These developments highlight Insmed’s strategic focus on addressing unmet medical needs in rare diseases, positioning it favorably in niche markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.